Personalizing
Cancer Treatment for Everyone

PUBLISHED RESEARCH
Docetaxel-based chemotherapy led to significant improvement in progression-free (PFS) and overall survival for patients
Overall Survival Rate Increased in Gastric Cancer

Docetaxel-based chemotherapy led to significant improvement in progression-free (PFS) and overall survival for patients with resectable gastric or gastroesophageal juncture (GEJ) cancer, according to a study reported at the European Society for Medical Oncology conference in Madrid.

285
Liposuction Reduces Swelling and Pain Associated with Lymphedema

Liposuction for primary or secondary lymphedema led to substantial reductions in limb swelling and associated pain, according to a case report in the New England Journal of Medicine.

286
PARP Inhibitor Active in Non-BRCA Breast Tumors

A PARP inhibitor demonstrated activity in triple-negative breast cancer (TNBC) xenografts without BRCA1/2 mutations, investigators reported online in Clinical Cancer Research.

287
Immunotherapy Response Related to Bacteria in the Gut

The types and diversity of gut bacteria had a significant association with response to anti-PD-1 immunotherapy, according to two studies published in Science.

280
Searching for the ovarian cancer cell of origin

Although there are several types of ovarian cancer, high-grade serous ovarian carcinomas are the most common. These cancers carry a poor prognosis and have historically been thought of as originating from the ovarian surface epithelium. However, several recent reports have raised the possibility that the fallopian tube epithelium is the actual origin of this deadly cancer, yet definitive evidence was lacking.

270
Virtual Tumor Board Shows Promise
Trial access promoted, cost of care reduced

Evaluation of patients with advanced cancers by a virtual tumor board in precision oncology matched most patients with clinical trials and substantially reduced the cost of care, according to a small pilot study.

269
Sequencing Boosts Standard of Care

Drug development in oncology continues to experience high failure rate. We now understand that tumors are heterogeneous and dynamic, and we are seeing the importance of stratifying patients as well as continuously monitoring for resistant mutations. These measures may improve response rates to targeted therapies and their survival benefit.

260
Sinomenine inhibits ovarian cancer cell growth and metastasis by mediating the Wnt/β-catenin

Sinomenine (SIN), an isoquinoline isolated from the Chinese medicinal plant Sinomenium acutum, is well known for its curative effect on rheumatic and arthritic diseases. Recently, SIN has been reported to possess potent anti-tumor effects in various types of cancers. However, the role and the underlying mechanism of the inhibitory action of SIN on ovarian cancer remain unknown.

261
FDA Approves Second CAR T-Cell Therapy
Axi-cel for adults with certain B-cell lymphomas
The FDA approved the chimeric antigen receptor (CAR) T-cell agent axicabtagene ciloleucel (axi-cel, Yescarta) for adults with certain types of relapsed or refractory large B-cell lymphoma. (MedPage Today)
195
Dabrafenib plus trametinib in patients with previously untreated -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

BRAFV600E mutation occurs in 1–2% of lung adenocarcinomas and acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown substantial antitumour activity in patients with previously treated BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC). The researchers aimed to assess the activity and safety of dabrafenib plus trametinib treatment in previously untreated patients with BRAFV600E-mutant metastatic NSCLC.

 
194
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. The researchers wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma.

Stay in Touch with Us
To speak with a dedicated cancer care specialist, contact us by one of the options listed below:
PLEASE FILL OUT FORM BELOW

X
Talk to Cancer Care Experts:
+1 (844) 627-7246
Top